Business Context and Reporting Period
Company: The Joint Corp. (JYNT)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2025
Business Model: Franchisor and operator of chiropractic clinics using a private-pay, non-insurance model. The company is executing a strategic shift to a "pure-play" franchisor by divesting all company-owned or managed clinics, which are now classified as discontinued operations.
Key Financial Metrics
| Metric | 2025 | 2024 |
|---|---|---|
| Total Revenues (Continuing Ops) | $54.9 million | $52.2 million |
| Net Income (Loss) | $2.9 million | $(5.8) million |
| Net Income from Discontinued Ops | $3.2 million | $(4.2) million |
| Net Loss from Continuing Ops | $(0.3) million | $(1.6) million |
| Adjusted EBITDA (Total) | $13.0 million | $11.4 million |
| Cash and Cash Equivalents | $23.6 million | $25.1 million |
| Operating Cash Flow | $1.8 million | $9.4 million |
| System-Wide Sales (Non-GAAP) | $532.4 million | $530.3 million |
| Active Clinics | 960 (885 Franchised, 75 Company-Owned) | 967 (842 Franchised, 125 Company-Owned) |
Material Changes vs. Prior Period
- Strategic Divestitures: Completed 41 clinic divestitures in 2025 and entered an agreement to sell 22 additional clinics. The company-owned clinic segment is now reported as discontinued operations.
- Revenue Growth: Total revenues from continuing operations increased 5.2% to $54.9 million, driven by royalty fees and advertising fund revenue growth due to an expanded franchise base.
- Profitability: The company returned to net profitability ($2.9 million) in 2025 compared to a net loss of $5.8 million in 2024, primarily due to income from discontinued operations ($3.2 million) offsetting a loss from continuing operations ($0.3 million).
- Stock Repurchases: Repurchased $11.3 million of common stock in 2025 under the 2025 Stock Repurchase Program (SRP).
- Leadership Changes: Sanjiv Razdan became CEO in October 2024, and Scott J. Bowman became CFO in June 2025.
Guidance, Outlook, and Risks
- Outlook: Management expects 2026 to remain a volatile macroeconomic environment with persistent inflation and elevated interest rates. The focus remains on refranchising the remaining company-owned clinics to generate proceeds for capital allocation (marketing, IT, M&A, or buybacks).
- Debt Covenant Default: As of December 31, 2025, the company is in default of its Credit Facility due to a violation of the fixed charge coverage ratio covenant, primarily caused by stock repurchases. This prohibits drawing on the $20.0 million revolver until resolved. Management expects to amend the covenant in the first half of 2026.
- Internal Controls: A material weakness in internal controls over financial reporting (related to asset impairment accounting) identified in 2024 has been remediated as of December 31, 2025.
- Restatements: The company restated financial statements for 2023, 2024, and Q1 2025 due to errors in asset valuation accounting and regional developer rights accounting.
- Risks: Key risks include labor shortages affecting clinic staffing, regulatory challenges regarding the "corporate practice of chiropractic" in various states, and potential litigation related to privacy and employment matters.
Investor Verification Checklist
- Debt Covenant Status: Verify the timeline and likelihood of amending the fixed charge coverage ratio covenant to restore access to the $20 million credit facility.
- Refranchising Progress: Monitor the closing of the 22 clinics under the December 2025 Asset Purchase Agreement and the sale of the remaining 75 company-owned clinics.
- Continuing Operations Profitability: Assess the path to profitability for the continuing franchise operations segment, which reported a net loss of $0.3 million in 2025.
- Legal Contingencies: Review updates on the California class action lawsuit and other employment-related litigation, which could result in significant liabilities.
- Internal Control Remediation: Confirm that the remediation of the material weakness in internal controls remains effective in future reporting periods.